Maree Zinzley, Manager Approvals Operations of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), that the following application has been made to register a trade name product under section 9(1) of the Act:

Trade Name: CLiK Extra Spray-On

Reference: A011384

Active Ingredient and Concentration:

Dicyclanil* 65g/L

Formulation Type: Aqueous suspension

General Use Claim:

For the control by prevention of blowfly strike for up to 22 weeks in sheep.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

1. must state in full the reasons for making the submission; and
2. may state any decision sought on that application; and
3. must be received by the director-general no later than 30 working days after the date of notification in the New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.

The following address is:

1. where submissions on this application are to be sent; and
2. where requests for copies of the public information relating to the application can be sent; and
3. where public information relating to the application can be viewed; and
4. the director-general’s address for service:

ACVM Group, Ministry for Primary Industries, Pastoral House, 25 The Terrace, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140.

The applicant’s address for service is:

Elanco Animal Health (a division of Eli Lilly and Company (NZ) Limited), Level 1, 123 Ormiston Road, Botany Junction, Auckland. Postal Address: 112 Wharf Road, West Ryde, New South Wales, Australia.

Dated at Wellington this 7th day of November 2016.

MAREE ZINZLEY, Manager Approvals Operations, Ministry for Primary Industries (acting under delegated authority).

*Concentration of active is greater than that approved for any similar product. This application is being publicly notified because the dose of active ingredient administered per kilogram liveweight is greater for this product than other dicyclanil-based products currently registered, resulting in a different risk profile.